Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma

J Immunother Cancer. 2023 Mar;11(3):e006361. doi: 10.1136/jitc-2022-006361.

Abstract

Advanced renal cell carcinoma is a biologically heterogeneous disease with multiple treatment options that largely involve immunotherapy and/or anti-angiogenic therapies. The choice of initial and subsequent therapy depends on both clinical and biological considerations. Here, we describe the application of recent data to clinical practice.

Keywords: Clinical Trials as Topic; Immunotherapy; Kidney Neoplasms.

MeSH terms

  • Carcinoma, Renal Cell* / drug therapy
  • Humans
  • Immunotherapy
  • Kidney Neoplasms* / drug therapy